Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II teclistamab trial in previously treated AL amyloidosis
2024-519191-90-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of teclistamab in light-chain amyloidosis, sponsored by European Myeloma Network. Primary endpoint: Hematologic complete response rate at 3 cycles. Planned start Jul 2025; status: authorised.
02
Drugs
teclistamab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2024-519191-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519191-90-00.